One surgeon performed all the operations which consisted ofjoining the proximal twelve inches ofjejunum, end-to-end, to the ileum six inches from the ileocecal valve.4 In patient C.P. the jejunum was anastomosed directly to the cecum because the distal stump of the ileum became ischemic after transection. The distal end of the jejunum was closed and the proximal end of the ileum was anastomosed end-to-side to the ascending colon.
The only medications permitted during the studies were sleeping medications (chloral hydrate, flurazepam hydrochloride) and anti-inflammatory drugs (indomethacin, aspirin, acetaminophen). One patient, H.R., took codeine for relief of arthritic pain during her first study.
Study Protocol
The patients received 1.0 mg of digoxin on the first day (four tablets of digoxin, 0.25 mg). Thereafter, they took 0.5 mg of digoxin (two tablets in the morning) daily for the next eight days. Digoxin was given as Lanoxin tablets (Lot no. 772B). In vitro tests performed by the Burroughs Wellcome Company demonstrated that 69% of digoxin was in solution within one hour. The patients were admitted to the hospital the evening of the seventh day of each study. Twenty-four hour urine collections were obtained on day 9 in order to determine total urinary creatinine and digoxin excretion as well as creatinine and digoxin clearance. Blood samples for steady state serum digoxin levels were drawn 24 hours after the previously administered dose on days 7, 8, and 9. On day 9, blood was also drawn at the following times: ½/2, 1, 11/2, 2, 3, 6, 8, 12 and 24 hours following administration of the 0.5 mg oral dose ( fig. 1 ). The 24 hour area under the serum concentration time curve (AUC) was measured by the trapezoidal rule, and the renal clearance determined by dividing the total amount of digoxin eliminated in the urine during the 24 hours by the AUC for the same time interval. Blood was drawn each morning for five consecutive days after the last dose of digoxin was administered in order to calculate the biologic half-life of digoxin.
Tests of malabsorption included serum carotene, total protein and serum albumin. Two consecutive 24-hour collections of stool were analyzed for fecal fat. The dietary intake of fat was not controlled. A d-xylose tolerance test was performed on day 10 . Urine was collected and analyzed for d-xylose after administration of 5 g of d-xylose dissolved in 250 ml of water. The serum concentration of d-xylose was measured 1, 2, 5, and 8 hours after d-xylose was given. Serum drawn on day 8 was analyzed for blood urea nitrogen, creatinine, glucose, sodium, potassium, CO2, chloride, SGOT, thyroxine and prothrombin time. A complete blood count and urinalysis were also obtained. The same protocol was repeated after surgery.
Methods
Details of the tritium radioimmunoassay for digoxin in plasma have been described previously., The standard solutions were prepared in human pooled plasma in a concentration of 0-4 ng/ml. Digoxin concentration in urine was assayed as follows. One ml of urine was diluted with 19 ml of plasma. This solution was assayed in triplicate using 0.5 ml aliquots. An equal amount of blank urine was added to each plasma standard. The digoxin radioimmunoassay involved incubation of the sample with digoxin specific antiserum and 3H-digoxin. Dextran-coated charcoal was used to separate unbound isotope from that bound to antiserum. The supernatant containing the antibody-3H-digoxin complex was counted in a liquid scintillation spectrometer. The standard curve for each assay was a straight line obtained by plotting the reciprocal of the disintegrations per minute versus digoxin concentration at each standard point. The digoxin concentrations for the patient serum or urine samples were calculated after the slope and the intercept of the standard curve were obtained.
Total serum protein was determined by the biuret method; The data were statistically analyzed using the Student's paired t-test. Results Jejunoileal bypass in our patients caused definite malabsorption as evidenced by a significant decrease in urine AUCs are adjusted for differences in body weight before and digoxin serum concentrations did not differ significantly after surgery the apparent differences in bioavailability are before and after surgery. The ratio of these values indicates reduced and the average ratio of these respective parameters that the average digoxin bioavailability in these patients approaches 1.0. In addition, these adjusted ratios agree after surgery is 87% of that prior to surgery. Another way of closely with the ratios of urinary digoxin recovery before evaluating bioavailability is to compare the AUCs during a and after surgery. The urine data are based upon the results 
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VOL 55, No 3, MARCH 1977 in four subjects since there was incomplete urine collection in three patients. There was no statistical difference in the mean serum halflife after surgery (P < 0.1). The mean values were 1.18 ± 0.22 days before and 1.36 + 0.21 days after bypass in the five patients with adequate data for analysis.
Discussion
These results indicate that there is no apparent impairment of absorption of digoxin from the tablets employed in this study after removal of the distal jejunum and proximal ileum even though definite evidence of malabsorption was documented in all our patients. When assessing bioavailability from serum concentration data one usually assumes drug clearance from the body in a given patient to be constant. However, the influence of jejunoileal bypass surgery on the disposition kinetics of digoxin or drugs in general is not known. As a result any changes which surgery of this type may produce in digoxin clearance could influence the interpretation of these data. No apparent change was observed in the biologic half-life of digoxin in patients after surgery. It is difficult from the data obtained to determine whether or not there were any changes in the apparent volume of distribution and hence any changes in digoxin clearance. Since digoxin is cleared primarily by the kidney, and since no apparent changes in the half-life and renal clearance of digoxin were observed, it would appear that the apparent volume of distribution of digoxin was unchanged. If the loss in weight after surgery was due to a loss in adipose tissue only, no adjustments in plasma levels and AUCs would be required, since there is insignificant distribution of digoxin into adipose tissue" and the same dose per kg lean body weight would have been administered. However, it is possible that the loss in weight after jejunoileal bypass surgery may be a consequence of a loss in both adipose and muscle tissue,7 and steady-state serum concentrations and AUCs should be normalized for changes in body weight. This has been done in table 2 and results in a slight but insignificant increase in the ratios of steady-state plasma concentrations and AUCs.
It has been suggested that measurement of urinary excretion of digoxin is less variable and perhaps a more valid measure of digoxin bioavailability than serum concentrations or AUCs.8-10 In the present study urine and serum data agree very well. However, the urine data only represent the results of four subjects and hence this comparison is incomplete. In those subjects where digoxin excretion was determined, approximately 50% of the oral dose was recovered in the urine prior to surgery (range 36-61%) and 44% after surgery (range 33-59%). These mean urinary recoveries of digoxin are consistent with the reports of other investigators using digoxin elixir or tablet formulations that had rapid dissolution.9 10 The data in the present study are consistent with the findings consecutive cases were encountered in whom VF was sustained and completely resistant to the conventional forms of electrical and pharmacological resuscitative therapy over a 30-minute period. These 27 cases form the basis of this report. Twenty-one of these patients had ischemic heart disease, two patients were recovering from aortic valve replacement, and one each had subacute bacterial endocarditis, renal failure, digitalis toxicity, and trauma.
The composition and operation of the mobile cardiac arrest team has been described in a previous report. 10 Briefly, the four-member team was gathered in the CCU and consisted of a senior and junior house officer attached to the acute care cardiorespiratory service, a specially trained nurse and an inhalation therapist. All 
